
GYNECOLOGIC CANCERS
Latest News
Video Series

Latest Videos
More News

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.

ZW191 is engineered to bind to FRα, a cell-surface protein with high expression across several tumor types.

Final results from the phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves overall survival in newly diagnosed advanced ovarian cancer.

FDA approves relacorilant for platinum-resistant ovarian cancer, showing significant survival benefits without added safety risks in clinical trials.

FDA clears MyChoice CDx to find HRD-positive advanced ovarian cancer patients for niraparib, using BRCA and genomic instability testing.

COMPASSION-03 follow-up shows cadonilimab delivers durable survival in recurrent/metastatic cervical cancer, including PD‑L1–negative patients.

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.


Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

Screening rates fall as many women seek privacy and convenience; FDA‑cleared home HPV self-sampling may boost access and reduce disparities.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

Experts debate MMR/p53 testing, liquid biopsy, and immunotherapy sequencing in endometrial cancer, refining prognosis and relapse treatment.



















































